Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
Nikolaidis CInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.
Ming CInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.
Pedrazzani CInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.
van der Horst TInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.
Kaiser-Grolimund AInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.
Ademi ZEuropean Center of Pharmaceutical Medicine, University of Basel, Basel, Switzerland.
Bührer-Landolt RUniversity Clinic for Medical Oncology, Inselspital Bern, Bern, Switzerland.
Bürki NWomen's Clinic and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
Caiata-Zufferey MUniversity of Applied Sciences and Arts of Southern Switzerland, Manno, Switzerland.
Champion VIndiana University School of Nursing, Indianapolis, Indiana, USA.
Chappuis PODivision of Genetic Medicine, Geneva University Hospitals, University of Geneva, Geneva, Switzerland.
Kohler CInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland.
Erlanger TEClinical Trial Unit, Department of Clinical Research, University Hospital Basel, Basel, Switzerland.
Graffeo RInstitute of Oncology and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
Hampel HDivision of Human Genetics, Department of Internal Medicine, Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Heinimann KInstitute for Medical Genetics and Pathology, University Hospital Basel, and Research Group Human Genomics, Department of Biomedicine, University of Basel, Basel, Switzerland.
Heinzelmann-Schwarz VWomen's Clinic and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
Kurzeder CWomen's Clinic and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
Monnerat COncology Services, Hospital of Jura, Delémont, Switzerland.
Northouse LLUniversity of Michigan School of Nursing, Ann Arbor, Michigan, USA.
Pagani OInstitute of Oncology and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
Probst-Hensch NSwiss Tropical and Public Health Institute, University of Basel, Basel, Switzerland.
Rabaglio MUniversity Clinic for Medical Oncology, Inselspital Bern, Bern, Switzerland.
Schoenau EWomen's Clinic and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
Sijbrands EJGDepartment of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.
Taborelli MInstitute of Oncology and Breast Unit of Southern Switzerland, Bellinzona, Switzerland.
Urech CWomen's Clinic and Gynecological Oncology, University Hospital Basel, University of Basel, Basel, Switzerland.
Viassolo VUnit of Oncogenetics and Cancer Prevention, Division of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Wieser SWinterthur Institute of Health Economics, Zurich University of Applied Sciences, Winterthur, Switzerland.
Katapodi MCInstitute of Nursing Science, Department of Public Health, University of Basel, Basel, Switzerland, maria.katapodi@unibas.ch.
English
BACKGROUND An international workshop on cancer predisposition cascade genetic screening for hereditary breast and ovarian cancer (HBOC) and Lynch syndrome (LS) took place in Switzerland, with leading researchers and clinicians in cascade screening and hereditary cancer from different disciplines. The purpose of the workshop was to enhance the implementation of cascade genetic screening in Switzerland. Participants discussed the challenges and opportunities associated with cascade screening for HBOC and LS in Switzerland (CASCADE study); family implications and the need for family-based interventions; the need to evaluate the cost-effectiveness of cascade genetic screening; and interprofessional collaboration needed to lead this initiative.
METHODS The workshop aims were achieved through exchange of data and experiences from successful cascade screening programs in the Netherlands, Australia, and the state of Ohio, USA; Swiss-based studies and scientific experience that support cancer cascade screening in Switzerland; programs of research in psychosocial oncology and family-based studies; data from previous cost-effectiveness analyses of cascade genetic screening in the Netherlands and in Australia; and organizational experience from a large interprofessional collaborative. Scientific presentations were recorded and discussions were synthesized to present the workshop findings.
RESULTS The key elements of successful implementation of cascade genetic screening are a supportive network of stakeholders and connection to complementary initiatives; sample size and recruitment of relatives; centralized organization of services; data-based cost-effectiveness analyses; transparent organization of the initiative; and continuous funding.
CONCLUSIONS This paper describes the processes and key findings of an international workshop on cancer predisposition cascade screening, which will guide the CASCADE study in Switzerland.